Disease · MONDO_0005556
lupus nephritis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. lupus nephritis. Diseases, record MONDO_0005556. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005556
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Approval, for 2 of its 88 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD
- Open Targets
Drugs88
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| VOCLOSPORIN | CHEMBL5314379 | Protein | Approval | EMA Human Drugs, FDA, PMDA and TTD | 14 | 10 | 10 | Drugs and targets |
| BELIMUMAB | CHEMBL1789843 | Antibody | Approval | DailyMed | 9 | 8 | 8 | Drugs and targets |
| MYCOPHENOLATE MOFETIL | CHEMBL1456 | Small molecule | Phase 3 | ClinicalTrials.gov | 30 | 30 | 30 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 27 | 27 | 27 | Drugs and targets |
| AZATHIOPRINE | CHEMBL1542 | Small molecule | Phase 3 | ClinicalTrials.gov | 13 | 13 | 13 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 3 | ClinicalTrials.gov | 12 | 12 | 12 | Drugs and targets |
| TACROLIMUS | CHEMBL3989887 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 7 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 3 | Drugs and targets |
| OBINUTUZUMAB | CHEMBL1743048 | Antibody | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
1 to 10 of 88
See all 88 drugsTargets108
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 12 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| IMPDH1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 4 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 3 | https://conductscience.org/library/genes/3614 | Drugs and targets |
| IMPDH2 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 4 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 3 | https://conductscience.org/library/genes/3615 | Drugs and targets |
| MS4A1 | B-lymphocyte antigen CD20 | 4 | B-lymphocyte antigen CD20 binding agent | Phase 3 | https://conductscience.org/library/genes/931 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 3 | FK506-binding protein 1A inhibitor | Phase 3 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| CD19 | B-lymphocyte antigen CD19 | 2 | B-lymphocyte antigen CD19 binding agent | Phase 2 | https://conductscience.org/library/genes/930 | Drugs and targets |
| CD38 | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 | 2 | Lymphocyte differentiation antigen CD38 inhibitor | Phase 2 | https://conductscience.org/library/genes/952 | Drugs and targets |
| CD3D | T cell surface glycoprotein CD3 | 2 | T cell surface glycoprotein CD3 binding agent | Phase 2 | https://conductscience.org/library/genes/915 | Drugs and targets |
| CD3E | T cell surface glycoprotein CD3 | 2 | T cell surface glycoprotein CD3 binding agent | Phase 2 | https://conductscience.org/library/genes/916 | Drugs and targets |
| CD3G | T cell surface glycoprotein CD3 | 2 | T cell surface glycoprotein CD3 binding agent | Phase 2 | https://conductscience.org/library/genes/917 | Drugs and targets |
1 to 10 of 108
See all 108 targetsTrials141
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01714817 | Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis | Phase 3 | 695 | 2017-12-21 | Lupus Nephritis | ABATACEPT | Its record names the disease | ClinicalTrials.gov |
| NCT01639339 | Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis | Phase 3 | 448 | 2020-07-07 | Lupus Nephritis | BELIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00430677 | Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis | Phase 2/3 | 423 | 2012-05-11 | Systemic Lupus Erythematosus | ABATACEPT, MYCOPHENOLATE MOFETIL, PREDNISONE | Its record names the disease | ClinicalTrials.gov |
| NCT00377637 | A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis. | Phase 3 | 370 | 2011-12-06 | Lupus Nephritis | CYCLOPHOSPHAMIDE, MYCOPHENOLATE MOFETIL | Its record names the disease | ClinicalTrials.gov |
| NCT03021499 | Aurinia Renal Response in Active Lupus With Voclosporin | Phase 3 | 358 | 2021-06-16 | Lupus Nephritis | VOCLOSPORIN | Its record names the disease | ClinicalTrials.gov |
| NCT01499355 | BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis | Phase 2 | 276 | 2017-01-18 | Lupus Nephritis | BIIB-023 | Its record names the disease | ClinicalTrials.gov |
| NCT04181762 | Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis | Phase 3 | 275 | 2024-10-10 | Lupus Nephritis | SECUKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04221477 | A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis | Phase 3 | 271 | 2025-11-06 | Lupus Nephritis | OBINUTUZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02141672 | AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV) | Phase 2 | 265 | 2021-05-18 | Lupus Nephritis | VOCLOSPORIN | Its record names the disease | ClinicalTrials.gov |
| NCT03597464 | Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin | Phase 3 | 216 | 2022-12-14 | Lupus Nephritis | VOCLOSPORIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 141
See all 141 trialsComparisons in its trials71
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Belimumab 10 mg/kg vs Placebo: Double-blind Period: Number of Participants With Time to Death or Renal Related Event | 35 of 223 | 63 of 223 | 446 | NCT01639339 | Trial comparisons |
| Abatacept IV vs Placebo IV: Number of Participants With Abatacept Induced Antibody Response Over Time in the Double-blind Period | 7 of 202 | 9 of 203 | 405 | NCT01714817 | Trial comparisons |
| Abatacept IV vs Placebo IV: deaths from any cause | 7 of 202 | 6 of 203 | 405 | NCT01714817 | Trial comparisons |
| Abatacept IV vs Placebo IV: serious adverse events | 62 of 202 | 58 of 203 | 405 | NCT01714817 | Trial comparisons |
| Voclosporin vs Placebo Oral Capsule: deaths from any cause | 1 of 178 | 5 of 178 | 356 | NCT03021499 | Trial comparisons |
| Voclosporin vs Placebo Oral Capsule: serious adverse events | 37 of 178 | 38 of 178 | 356 | NCT03021499 | Trial comparisons |
| Secukinumab 300 mg vs Placebo: deaths from any cause | 1 of 137 | 1 of 138 | 275 | NCT04181762 | Trial comparisons |
| Secukinumab 300 mg vs Placebo: serious adverse events | 30 of 137 | 39 of 138 | 275 | NCT04181762 | Trial comparisons |
| Obinutuzumab vs Placebo: Number of Participants With Adverse Events (AEs) | 126 of 136 | 117 of 132 | 268 | NCT04221477 | Trial comparisons |
| Obinutuzumab vs Placebo: deaths from any cause | 5 of 136 | 4 of 132 | 268 | NCT04221477 | Trial comparisons |
1 to 10 of 71
See all 71 comparisons in its trialsPapers from its trials78
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005556
GET https://conductscience.org/api/diseases/v1/MONDO_0005556/drugs?page=2